Figure 3
From: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer
miR-29b targets p85α and CDC42, and determines the effects of S100A7 on p53 activation and stability in different cells. (A) target sites of miR-29b on 3′ UTRs of CDC42 and p85α mRNAs. (B) WB of p53, p85α and CDC42. β-actin is loading control. (C) miR-29b knockdown by antagomir inhibitor in MCF7-S cells. (D) WB of transient miR-29b inhibitor transfection partially rescuing p85α and CDC42 protein expression in MCF7-S cells. (E) prolonged knock down of miR-29b with miR-29b-Decoy reduced p53 phosphorylation and total p53 level in MCF7-S cells. (F) Confocal microscopy of phosphorylated p53 localization in MCF7-V and MCF7-S cells. Nuclei were labelled with DAPI. (G) relative p53 levels in nuclear extract of cells. p53 levels were normalized to nuclear marker Oct1. (H) total p53 levels of cells indicating the stability of p53. (*p < 0.05, **p < 0.01).